RecruitingNot ApplicableNCT05231915

Prevalence of the c.853delT Mutation of the HOXB13 Gene in Prostate Cancer in Martinique

Sponsor

University Hospital Center of Martinique

Enrollment

465 participants

Start Date

Apr 9, 2021

Study Type

INTERVENTIONAL

Conditions

Prostate Cancer

Summary

In Martinique, prostate cancer incidence rates are nowadays among the highest worldwide with a high incidence of early-onset and familial forms. We identified a rare heterozygous germline variant c.853delT (p.Ter285Lysfs) rs77179853, reported only among patients of African ancestry with a minor allele frequency of 3.2%. We search to estimate the prevalence of this variant in a sample of prevalent prostate cancer cases managed in urology consultation in Martinique .

Eligibility

Sex: MALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating how common a specific genetic mutation (c.853delT in the HOXB13 gene) is among men with prostate cancer living in Martinique (a French Caribbean island), and whether this mutation is linked to hereditary or more aggressive forms of the disease. **You may be eligible if...** - You are an adult man (18 or older) living in Martinique - You have been diagnosed with prostate cancer (any type or stage) - You are being managed at a urology clinic in Martinique (public or private) - You are a beneficiary of French social security - You have given written informed consent **You may NOT be eligible if...** - You have a history of other cancers that could confound the study - You are unable to give informed consent - You do not meet the local inclusion criteria set by the investigators Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.